Consolidated income Statement
Show table
| € million | Note | 2014 | 2013 |
|---|---|---|---|
| Sales | → 23 | 11,291.5 | 10,700.1 |
| Royalty, license and commission income | → 24 | 209.3 | 395.0 |
| Total revenues | 11,500.8 | 11,095.1 | |
| Cost of sales1 | → 25 | – 3,526.4 | – 3,041.7 |
| (of which: amortization of intangible assets)1 | (– 94.0) | (– 49.2) | |
| Gross profit1 | 7,974.4 | 8,053.4 | |
| Marketing and selling expenses1 | → 26 | – 3,104.9 | – 3,088.5 |
| (of which: amortization of intangible assets)1 | (– 719.0) | (– 762.0) | |
| Royalty, license and commission expenses | → 27 | – 537.5 | – 567.0 |
| Administration expenses | → 28 | – 608.6 | – 562.4 |
| Research and development costs1 | → 29 | – 1,703.7 | – 1,506.6 |
| (of which: amortization of intangible assets)1 | (– 3.8) | (– 2.3) | |
| Other operating expenses and income | → 30 | – 257.7 | – 718.1 |
| Operating result (EBIT) | 1,762.0 | 1,610.8 | |
| Financial result | → 31 | – 205.0 | – 222.2 |
| Profit before income tax | 1,557.0 | 1,388.6 | |
| Income tax | → 32 | – 392.2 | – 179.5 |
| Profit after tax | 1,164.8 | 1,209.1 | |
| of which attributable to Merck KGaA shareholders (net income) | 1,157.3 | 1,202.2 | |
| of which attributable to non-controlling interests | → 33 | 7.5 | 6.9 |
| Earnings per share (in €) | → 34 | ||
| basic2 | 2.66 | 2.77 | |
| diluted2 | 2.66 | 2.77 | |
|
|||